Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

White paper helps industry navigate new NHS roadmap

August 24, 2020 | Covid-19 recovery, NHS Reset 

New report shows how pharma can support the NHS in the Covid-19 recovery era

As the pandemic response in the UK moves on to ‘phase 3’, and the NHS plans to make a gradual return to pre-Covid-19 service levels, pharma must define how its products and services fit into the new roadmap that has been created.

In a bid to answer some of these questions for industry, healthcare intelligence provider Wilmington Healthcare has published a white paper, entitled “Covid-19: Roadmap to Recovery”.

The white paper looks at the next stages in the recovery process for the NHS and explores how industry can support the health service as it faces a multitude of challenges, including dealing with the care backlog and Covid-19 aftercare.

It covers three major areas, the first two of which are the NHS Reset initiative and its attendant policies; followed by the status and aims of the various NHS stakeholders tasked with taking the service through the next phase.

It also tackles issues surrounding NHS recovery from the point of view of pharma and defines the issues that are affecting it from access and digital engagement to the role of new NHS pathways.

The need to respond at scale and pace to the coronavirus pandemic has created unprecedented collaboration between the NHS and pharma in areas such as protection of supply chains and rapid development of Covid-19 drugs and vaccines. The challenge now is to maintain and strengthen partnership working.

Oli Hudson, Content Director at Wilmington Healthcare and one of the authors of the white paper, said “As the NHS resets, it will require innovation, technology, new pathways and new solutions to the various issues emerging from Covid-19. Industry needs to identify the right stakeholders and develop propositions tailored to their changing needs.

“With the right brand strategy and approach, some very promising new partnerships can be formed. This white paper aims to give industry powerful insights into the opportunities that are emerging and help it define how to support the NHS through the challenges that lie ahead.”

To register to download the free white paper visit http://ow.ly/yY3C30r5auA

Ends

This content was provided by Wilmington Healthcare

Company Details

Wilmington Healthcare

Wilmington Healthcare

Email
Website

 Latest Content from  Wilmington Healthcare 

Hear from her: Women's Health Faces Some Difficult Headwinds. Here's How We Can Move Forward

Considering a portfolio review?

Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE

With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES

As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...